FDA approves first wireless diabetes glucose monitoring app

diabetes illus250x03 FDA approves first wireless diabetes glucose monitoring appThe Food and Drug Administration (FDA) has approved the first seamless diabetes glucose monitoring app, which can wirelessly transmit glucose readings directly to an iPhone, giving diabetics more flexibility when it comes to managing their disease. Federal drug and medical device regulators gave a nod to the new version of the Dexcom Share platform, which works with the Dexcom G4 continuous glucose monitor (CGM).

The original Dexcom Share, which was approved by the FDA in October 2014, was a docking cradle peripheral that could transmit Dexcom’s glucose readings to a nearby iPhone. The readings were then uploaded through the cloud to caregivers. One drawback to the original device was that the Share Solution required a separate dock, which rendered it only viable in sedentary settings, such as overnight monitoring.

The newly approved version of Dexcom Share uses Bluetooth technology to replace the original G4 receiver, allowing it to transmit sugar readings directly to an iPhone app. The new G4 receiver will be available in March 2015.

The new system continuously transmits glucose readings from a sensor that is worn on the body through the new receiver to the iPhone. The Dexcom Share iPhone app will then transmit the data through the cloud to up to five user-approved followers with the Dexcom Follow iPhone app.

Dexcom is also developing another generation of its glucose monitor device that can transmit glucose data directly from the sensor on the patient’s body to the iPhone without need for a receiver.

Diabetes is a serious health issue. Patients must follow a specialized diet and regularly monitor their blood sugar levels to protect against complications. The majority of diabetics have type 2 diabetes and many of these patients will require lifelong medication to manage their disease.

Several type 2 diabetes medications have been linked to cancer risks. For example, Actos can increase the risk for bladder cancer, and newer drugs including Januvia and Byetta can cause pancreatic cancer, as well as a painful inflammation of the pancreas known as acute pancreatitis.

Source: iMedicalApps